Connect2Test for COVID-19 Pandemics

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Oregon, Eugene, OR
COVID-19 Pandemics+3 More
Connect2Test - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

People who inject drugs (PWIDs) are highly vulnerable to SARS-CoV-2 infection and to the disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), however, rates of SARS-CoV-2 testing and vaccination uptake -vital to mitigating the spread of COVID-19 and achieving herd immunity - are lower among PWIDs compared to the general population. Building on our Phase I Rapid Acceleration of Diagnostics project, which found that contingency management (CM) increased testing utilization among PWIDs, the proposed project evaluates the comparative effectiveness of CM versus CM plus a brief motivational enhancement intervention on SARS-CoV-2 testing and vaccination uptake among PWIDs. This project has the potential to reduce COVID-19 health disparities among PWIDs and to decrease population level COVID-19 morbidity and mortality.

Eligible Conditions

  • COVID-19 Pandemics

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: One time point only (~15 minute survey), when a participant engages in COVID-19 testing at a syringe exchange site, no longitudinal follow-up

One time point only (~15 minute survey), when a participant engages in COVID-19 testing at a syringe exchange site, no longitudinal follow-up
SARS-CoV-2 Testing
One time point only (~15 minute survey), when a participant engages in COVID-19 vaccination at a syringe exchange site, no longitudinal follow-up
COVID-19 Vaccination

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Contingency Management Alone
1 of 2
Connect2Test Intervention + Contingency Management
1 of 2
Active Control
Experimental Treatment

350 Total Participants · 2 Treatment Groups

Primary Treatment: Connect2Test · No Placebo Group · N/A

Connect2Test Intervention + Contingency Management
Behavioral
Experimental Group · 1 Intervention: Connect2Test · Intervention Types: Behavioral
Contingency Management Alone
Behavioral
ActiveComparator Group · 1 Intervention: Connect2Test · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: one time point only (~15 minute survey), when a participant engages in covid-19 testing at a syringe exchange site, no longitudinal follow-up
Closest Location: University of Oregon · Eugene, OR
Photo of oregon 1Photo of oregon 2Photo of oregon 3
2016First Recorded Clinical Trial
1 TrialsResearching COVID-19 Pandemics
25 CompletedClinical Trials

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,203 Previous Clinical Trials
5,610,129 Total Patients Enrolled
University of OregonLead Sponsor
61 Previous Clinical Trials
33,864 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.